Kisspeptin-10 dosing research protocols — short half-life, reconstitution, handling

“What is the Kisspeptin-10 dose?” is one of the most-searched questions about the KISS1R agonist — and the honest answer starts by refusing the premise twice over. There is no validated human dose, because Kisspeptin-10 is not an approved medicine. And even the dose figuresthat exist mean less than people assume, because the molecule is gone from the bloodstream in minutes. That pharmacokinetic fact — a single-digit-minute plasma half-life — dominates the whole dosing-research story. This spoke reports the administration figures from the published acute-pharmacology work descriptively, explains why the half-life reshapes everything, shows the reconstitution math, and is explicit throughout that this is a research reference, not a protocol to follow.

Why there is no validated human dose

Before any number appears, it is worth being clear about what kind of object a “Kisspeptin-10 dose” is. It is not an approved dosing instruction, because Kisspeptin-10 is not an approved medicine in any major regulatory jurisdiction — there is no regulator-reviewed label, no marketed strength, and no dose-ranging programme that ran to registration. The figures that circulate on forums and vendor pages are extrapolations: they reproduce the amounts that appeared in acute neuroendocrine experiments and present them as though they were established protocols. They are not.

That distinction is the point of this article, so it is worth stating plainly: nothing below is a recommendation, and there is no validated human dose of Kisspeptin-10 for any use. The published studies were designed to characterisethe molecule’s neuroendocrine signalling — to ask what KISS1R activation does to GnRH pulse generation and the downstream gonadotropin (LH / FSH) response — not to find a regimen for general use. Read every figure that follows as “what these studies administered”, never as “what to take”.

There is no validated human dose of Kisspeptin-10. The numbers that circulate are research-reference figures — what specific studies administered to observe a neuroendocrine response — not a protocol for any person to follow.

The short-half-life nuance — why it changes the dosing question

The fact that does the most work in the Kisspeptin-10 dosing literature is not a milligram figure at all — it is a clearance figure. Kisspeptin-10 has a very short circulating half-life, on the order of single-digit minutes in published human pharmacokinetic work, because plasma peptidases cleave the decapeptide rapidly once it reaches the bloodstream. A small, unprotected linear peptide like this is exactly the kind of substrate those enzymes dispatch quickly, and the consequence is that the molecule does not linger to maintain receptor engagement.

This single fact reshapes the entire dosing question. Because the compound is cleared in minutes, a single subcutaneous bolus produces only a transient neuroendocrine response: KISS1R activation triggers a burst of GnRH release and a measurable but brief rise in the gonadotropins (LH and FSH), and the signal then fades over minutes to a small number of hours as the peptide is degraded [1]. It is a pulse, not a plateau. That is why a “dose” in the casual sense — a number you give once — tells you very little about what KISS1R is actually doing over time.

It is also why the published research administration is structured the way it is. When the experimental objective is sustained KISS1R engagement rather than a single brief pulse, the studies use continuous infusion or repeated bolus administration to hold the molecule at the receptor across the observation window, rather than relying on one short-lived injection. The Pinilla review situates this in the bigger picture: the kisspeptin / KISS1R system is the gatekeeper of GnRH pulse generation, and the physiology it controls is itself pulsatile, so reproducing or probing that pulsatility experimentally requires administration schedules that respect the molecule’s rapid clearance [2].

A single Kisspeptin-10 bolus is a pulse, not a plateau. The single-digit-minute half-life is why research administration uses infusion or repeated bolus when sustained KISS1R engagement is the objective — and why one injection yields only a brief gonadotropin response.

The same pharmacokinetic limitation is what drives the academic interest in longer-acting analogues: modified kisspeptin peptides engineered to resist plasma-peptidase degradation, so that they can sustain KISS1R engagement without continuous infusion. Those analogues are research tools, not the supply-category standard — but their existence is the clearest signal that the short half-life of native Kisspeptin-10 is recognised across the field as the central practical constraint on how it can be administered in a study.

What the studies actually administered (descriptive)

The Kisspeptin-10 administration record is best read as a small set of acute-pharmacology experiments rather than a clinical guideline. The figures that exist were gathered to elicit and measure a neuroendocrine response, and each is described here as what that study administered, not as a regimen anyone should reproduce.

• The human acute-pharmacology signal. Dhillo and colleagues established the human neuroendocrine signal for the kisspeptin family: subcutaneous administration to healthy volunteers produced robust increases in plasma LH, FSH and testosterone, replicating in humans the GnRH-driven gonadotropin cascade seen in animal models [1]. This is the anchor human-administration record — and it describes what that study gave its participants to observe an acute response, not a treatment on offer here. Subsequent work extended the same acute pharmacology to Kisspeptin-10.
• The gatekeeper-axis context. The Pinilla review consolidates the position of the kisspeptin / KISS1R system as the upstream regulator of GnRH pulse generation, integrating neuroendocrine inputs and driving the downstream hypothalamic-pituitary-gonadal (HPG) axis [2]. It is the framework that explains why administration schedules matter: the physiology being probed is pulsatile, and a molecule cleared in minutes can only engage that system in matching short pulses unless it is infused.

The through-line is consistent: the administration figures that exist come from acute neuroendocrine investigation, designed to characterise KISS1R signalling and GnRH pulse generation, not to establish a regimen for general use. They describe experiments. They do not describe a validated human dose, and presenting them as one would misrepresent what the papers actually say.

Reconstitution & the syringe math

Chemically, Kisspeptin-10 is one of the more straightforward research peptides to handle. It is an amidated decapeptide — the C-terminal 10-residue active sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, molecular weight approximately 1,302 Da, supplied as the acetate salt — that is highly water-soluble and carries no disulphide bridges, so it dissolves readily and is not prone to the oxidative-folding problems that complicate larger, cysteine-containing peptides. The C-terminal amide is the natural, pharmacologically active form, which is exactly why the parent-ion and amidation checks on a certificate of analysis are meaningful.

Reconstitution mechanics, as a laboratory-handling procedure, are simple: introduce bacteriostatic water — sterile water with ~0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake: shaking shears and can denature the peptide. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide. The math below shows how a chosen mass in milligrams maps onto syringe units — it is laboratory-handling arithmetic, not a use instruction.

Storage & handling + amidation QC

As a lyophilised powder, Kisspeptin-10 is most stable at -20°C, protected from light; once reconstituted, the solution is generally kept refrigerated at 2-8°C and used within roughly 28 days, per short-peptide convention and the vendor’s documentation. Bacteriostatic water’s benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation.

The quality-control subtlety specific to this molecule is the C-terminal amidation. The amide form (the —Arg-Phe-NH₂ terminus) is the natural, pharmacologically active species; a non-amidated free-acid impurity would not behave the same way at KISS1R. So a research-grade material should arrive with documentation that confirms not just purity and mass but the amidation itself. Concretely: a third-party RP-HPLC purity assay of ≥98% peak area, mass-spectrometry confirmation of the parent ion at roughly 1,303 Da [M+H]⁺, and explicit confirmation of the C-terminal amidation. Without that documentation, the “dose” on the label is only as trustworthy as both the mass and the molecular form actually in the vial.

Cycles and “protocols” — convention vs evidence

The schedules that circulate online — a daily injection for a run of consecutive days, a break, a repeat — are presented as though they were established protocols. They are not derived from any published human dose-response work. They are convention: patterns that propagate through forums and vendor pages, often without reference to the one fact that should govern any such schedule, which is the molecule’s rapid clearance.

That is where the short half-life bites hardest. A circulating “protocol” built around a single daily bolus is, on the pharmacokinetics, a series of brief pulses with long gaps in between — it does not sustain KISS1R engagement, because the molecule is cleared within minutes of each injection [1]. The published work that did aim for sustained engagement reached for infusion or repeated dosing precisely to bridge those gaps, in keeping with the pulsatile gatekeeper physiology the Pinilla review describes [2]. So a single-bolus “cycle” is not a scaled-down version of the research administration — it is a different thing entirely, and nothing in the literature validates a particular dose, frequency, or course length for general use.

A circulating Kisspeptin-10 “protocol” is convention, not evidence. Because the half-life is single-digit minutes, single-bolus schedules cannot sustain target engagement — and no controlled human work has validated a dose, frequency, or course length for any use.

Related reading in the Kisspeptin-10 cluster

For what Kisspeptin-10 is and where its KISS1R pharmacology stands, start with the Kisspeptin-10 parent synopsis. For the molecular biology, see Kisspeptin-10 mechanism research; for its place at the apex of the axis, see Kisspeptin-10 and GnRH-axis research. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: Kisspeptin-10 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Dhillo et al. — J Clin Endocrinol Metab 2005. Human subcutaneous kisspeptin administration in healthy volunteers, with the acute neuroendocrine cascade — increases in plasma LH, FSH and testosterone. The anchor record for what the human acute-pharmacology work administered. PMID 16174713.
• [2] Pinilla, Aguilar et al. — Physiol Rev 2012. Consolidated review of the kisspeptin / KISS1R system as the gatekeeper of GnRH pulse generation — the pulsatile-physiology and axis context that explains why administration schedules must respect the molecule’s rapid clearance. PMID 22811428.

Last reviewed 12 June 2026. Kisspeptin-10 is not an approved medicine in any major jurisdiction; this article is research education and not medical advice, and nothing here describes a dose for any person to take. Wellness Labs supplies Kisspeptin-10 as research-grade lyophilised powder for non-clinical neuroendocrine and receptor-pharmacology investigation — research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.